Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Protest over planned cuts to Australian medical research funding

Australian medical researchers are protesting around the country following reports that funding to the sector could be cut in the May budget. The federal government is considering slashing $400 million from medical research.

11 Apr 2011

New treatment approach raises hope for women with ovarian cancer

Researchers at Oregon Health & Science University's Oregon National Primate Research Center may have good news for women at high-risk for ovarian cancer who also want to have children.

8 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 132 national research and training grants totaling $49,213,000 to 85 institutions nationwide in the second of two grants cycles for 2011.

5 Apr 2011

AACR President-elect to host press conference on cancer risk factors and genetics

As cancer continues to affect one in two men and one in three women, researchers are increasing their knowledge on the known risk factors for cancer both environmentally and genetically.

5 Apr 2011

Women with ovarian cancer having BRCA2 gene mutations are more likely to survive

Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation.

5 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2010.

30 Mar 2011

Longer Looks: Behind the hospital money curtain; Medical data breaches

Think you would stick to a diet if someone paid you for it? Would you be more likely to exercise if you were fined each time you bailed on your scheduled workout? Research in recent years suggests—and a handful of new businesses are betting—that you might.

25 Mar 2011

Philanthropists triple-match public's donations for TGen's unTEAL cure ovarian cancer event

Philanthropists Foster and Lynn Friess will triple-match the public's donations - up to a total of $100,000 - for TGen's 2nd annual unTEAL a cure ovarian cancer event.

21 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

Celebrity Chefs Cook Gala to support cancer research at UC San Diego

Top celebrity chefs from around the country will gather in San Diego April 16 for the 30th Celebrity Chefs Cook Gala benefiting research at the UC San Diego Moores Cancer Center. Themed "Epicurean Elegance: Food for the Mind, Body and Spirit," the gala will feature lush food artistry as 11 premiere chefs prepare their signature hors d'oeuvres paired with fine wine. Proceeds from the event will support the cancer center's most urgent needs.

19 Mar 2011

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.

17 Mar 2011

Scientist suggests breaking tangled mucus barrier can help treat cancer

Measuring the mechanical strength of cancer cell mucus layers provides clues about better ways to treat cancer, and also suggests why some cancer cells are more resistant to drugs than others, according to Kai-tak Wan, associate professor of engineering at Northeastern University, Boston, Mass.

17 Mar 2011

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Although finding effective screening tools remains a priority, new treatment options for women with ovarian cancer, such as the ones outlined in the updated NCCN Guidelines for Ovarian Cancer, are vital to making steady progress against the disease according to Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Ovarian Cancer.

16 Mar 2011

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

Vermillion, a molecular diagnostics company, today announced the presentation of positive preliminary data from its collaboration with Johns Hopkins University School of Medicine to identify biomarkers that improve on the specificity of CA125 for the identification of malignant ovarian tumors.

9 Mar 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Protest over planned cuts to Australian medical research funding

New treatment approach raises hope for women with ovarian cancer

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

AACR President-elect to host press conference on cancer risk factors and genetics

Women with ovarian cancer having BRCA2 gene mutations are more likely to survive

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

Longer Looks: Behind the hospital money curtain; Medical data breaches

Philanthropists triple-match public's donations for TGen's unTEAL cure ovarian cancer event

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Celebrity Chefs Cook Gala to support cancer research at UC San Diego

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

Scientist suggests breaking tangled mucus barrier can help treat cancer

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in